Regulation of Expression of Transforming Growth Factor-beta 2 by Transforming Growth Factor-beta Isoforms is Dependent upon Cell Type

被引:16
|
作者
O'reilly, Michael A. [1 ]
Danielpour, David [1 ]
Roberts, Anita B. [1 ]
Sporn, Michael B. [1 ]
机构
[1] NCI, Lab Chemoprevent, NIH, Bethesda, MD 20814 USA
关键词
gene expression; transforming growth factor-beta;
D O I
10.3109/08977199209026926
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The effect of three different isoforms of transforming growth factor-beta (TGF-beta) on the expression of TGF-beta 2 mRNA was studied in several continuous tumor cell lines. As previously reported for the mouse fibroblast cell line AKR-2B, the expression of TGF-beta 2 mRNA transcripts of 5.4, 4.7, 3.7 and 3.0 kb was decreased after a 24 hr treatment with 5 ng/ml of TGF-beta 1, TGF-beta 2 or TGF-beta 3. In A549, HBL-100 and BSC-1 epithelial cell lines, five distinct TGF-beta 2 mRNA transcripts of 5.8, 5.1, 4.0, 3.8 and 2.8 kb were detected by Northern blot analysis. Treatment of these cells with TGF-beta 1, TGF-beta 2 or TGF-beta 3 for 24 hr resulted in a 2-3 fold increase in the 5.8, 4.0 and 3.8 kb transcripts, with little detectable change in abundance of the 5.1 and 2.8 kb transcripts. The effect of the TGF-beta proteins was dose (5 ng/ml) and time (3-6 hr) dependent. A similar 2-3 fold increase in the level of secreted TGF-beta 2 was observed following treatment of A549 cells with TGF-beta 1. Basal level and induced expression of TGF-beta 2 mRNA in response to TGF-beta isoforms was decreased in the presence of actinomycin D. In all cell lines studied, the expression of the 2.5 kb TGF-beta 1 mRNA was relatively unchanged or markedly increased in response to treatment with TGF-beta. These studies support the hypothesis that expression of TGF-beta 2 is regulated by members of the TGF-beta family and is dependent upon cell type.
引用
收藏
页码:193 / 201
页数:10
相关论文
共 50 条
  • [11] Transforming growth factor-beta signaling in systemic sclerosis
    Ayers, Nolan B.
    Sun, Chenming
    Chen, Shi-You
    JOURNAL OF BIOMEDICAL RESEARCH, 2018, 32 (01): : 3 - 12
  • [12] Immunolocalization of transforming growth factor-beta in the bone tissue
    Hosoi, T
    Asaka, T
    Motoo, M
    Tomita, T
    Shiraki, M
    Inoue, S
    Ouchi, Y
    Orimo, H
    CALCIFIED TISSUE INTERNATIONAL, 1996, 59 (04) : 305 - 306
  • [13] Transforming Growth Factor-Beta and Urokinase Type Plasminoge Interplay in Cancer
    Santibanez, Juan F.
    Krstic, Jelena
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2018, 19 (12) : 1155 - 1163
  • [14] Activation of human vascular cells decreases their expression of transforming growth factor-beta
    Lebastchi, Amir H.
    Qin, Lingfeng
    Khan, Salman F.
    Zhou, Jing
    Geirsson, Arnar
    Kim, Richard W.
    Li, Wei
    Tellides, George
    ATHEROSCLEROSIS, 2011, 219 (02) : 417 - 424
  • [15] Uncoordinated regulation of mRNA expression of the three isoforms of transforming growth factor-beta in the mouse skin carcinogenesis model
    Rundhaug, JE
    Park, J
    Fischer, SM
    MOLECULAR CARCINOGENESIS, 1997, 18 (02) : 115 - 126
  • [16] Chronic Expression of Transforming Growth Factor-Beta Enhances Adult Neurogenesis
    Mathieu, Patricia
    Paula Piantanida, Ana
    Pitossi, Fernando
    NEUROIMMUNOMODULATION, 2010, 17 (03) : 200 - 201
  • [17] Regulation and interactions of transforming growth factor-beta with cardiovascular cells: Implications for development and disease
    Saltis, J
    Agrotis, A
    Bobik, A
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 (03): : 193 - 200
  • [18] The role of transforming growth factor-beta in primary brain tumors
    Rich, JN
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2003, 8 : E245 - E260
  • [19] DISTRIBUTION OF TRANSFORMING GROWTH FACTOR-BETA(1) IN HUMAN ASTROCYTOMAS
    HORST, HA
    SCHEITHAUER, BW
    KELLY, PJ
    KOVACH, JS
    HUMAN PATHOLOGY, 1992, 23 (11) : 1284 - 1288
  • [20] Transforming growth factor-beta and its implication in the malignancy of gliomas
    Roy, Laurent-Olivier
    Poirier, Marie-Belle
    Fortin, David
    TARGETED ONCOLOGY, 2015, 10 (01) : 1 - 14